|
|
||||||||
a Assistance Publique-Hôpitaux de Paris, Department of Cardiovascular Surgery, Bichat-Claude Bernard Hospital, Paris, France
b Assistance Publique-Hôpitaux de Paris, Department of Cardiology, Bichat-Claude Bernard Hospital, Paris, France
c Assistance Publique-Hôpitaux de Paris, Department of Thoracic and Vascular Surgery, Bichat-Claude Bernard Hospital, Paris, France
d Assistance Publique-Hôpitaux de Paris, Department of Anaesthesiology, Bichat-Claude Bernard Hospital, Paris, France
Accepted for publication March 17, 2009.
* Address correspondence to Dr Nataf, Department of Cardiac Surgery, Bichat Hospital, 46 rue Henri Huchard, Paris, 75018, France (Email: patrick.nataf{at}bch.aphp.fr).
Presented at the Forty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Francisco, CA, Jan 26–28, 2009.
Background: We describe the results of transcatheter aortic valve implantation (TAVI) in high-risk patients with aortic stenosis. Transfemoral access was the first option, and if contraindicated, the transapical approach was used.
Methods: Fifty patients were consecutively treated with TAVI because of high surgical risk or contraindications to operation. Mean age was 83 ± 6 years, and most were in New York Heart Association classes III and IV. The predicted surgical mortality was 28% ± 14% using the European System for Cardiac Operative Risk Evaluation and 16% ± 7% using the Society of Thoracic Surgeons Predicted Risk of Mortality. The Edwards-SAPIEN (Edwards Lifesciences Inc, Irvine, CA) valve was implanted using a transfemoral approach in 35 patients and the transapical approach in 15. The transapical patients had more comorbidity (diabetes, previous myocardial infarction, previous coronary artery bypass grafting, peripheral artery disease, renal failure, porcelain aorta, and previous stroke).
Results: Successful implantation was 85.7% and 100% in the transfemoral and transapical group, respectively. Gradients were satisfactory. In-hospital mortality was 8% in the transfemoral and 27% in the transapical group. Stroke was only observed in the transfemoral group. Overall 1-year survival was 74% ± 11% in the transfemoral group and 60% ± 13% in the transapical.
Conclusions: The results attributed to each approach (transfemoral or transapical) are strongly influenced by the selection strategy. Patients in the transapical group had more comorbidity and consequently a more critical early postoperative period. The respective places of transfemoral and transapical approaches need to be clarified for each approach by a randomized study.
This article has been cited by other articles:
![]() |
L. Henry, L. Halpin, S. Hunt, S. D. Holmes, and N. Ad Patient Disposition and Long-Term Outcomes After Valve Surgery in Octogenarians Ann. Thorac. Surg., September 1, 2012; 94(3): 744 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Descoutures, D. Himbert, C. Radu, B. Iung, C. Cueff, D. Messika-Zeitoun, G. Ducrocq, E. Brochet, P. Nataf, and A. Vahanian Transarterial Medtronic CoreValve System Implantation for Degenerated Surgically Implanted Aortic Prostheses Circ Cardiovasc Interv, October 1, 2011; 4(5): 488 - 494. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jacobs, M. Gessat, T. Walther, and V. Falk Three-dimensional template-based planning for transapical aortic valve implantation J. Thorac. Cardiovasc. Surg., June 1, 2011; 141(6): 1541 - 1543. [Full Text] [PDF] |
||||
![]() |
V. Falk, T. Walther, E. Schwammenthal, J. Strauch, D. Aicher, T. Wahlers, J. Schafers, A. Linke, and F. W. Mohr Transapical aortic valve implantation with a self-expanding anatomically oriented valve Eur. Heart J., April 1, 2011; 32(7): 878 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Johansson, S. Nozohoor, P. O. Kimblad, J. Harnek, G. K. Olivecrona, and J. Sjogren Transapical Versus Transfemoral Aortic Valve Implantation: A Comparison of Survival and Safety Ann. Thorac. Surg., January 1, 2011; 91(1): 57 - 63. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kempfert, A. Van Linden, A. Linke, G. Schuler, A. Rastan, S. Lehmann, L. Lehmkuhl, F.-W. Mohr, and T. Walther Transapical Aortic Valve Implantation: Therapy of Choice for Patients With Aortic Stenosis and Porcelain Aorta? Ann. Thorac. Surg., November 1, 2010; 90(5): 1457 - 1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Thielmann, D. Wendt, H. Eggebrecht, P. Kahlert, P. Massoudy, M. Kamler, R. Erbel, H. Jakob, and S. Sack Transcatheter Aortic Valve Implantation in Patients With Very High Risk for Conventional Aortic Valve Replacement Ann. Thorac. Surg., November 1, 2009; 88(5): 1468 - 1474. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Al-Attar, W. Ghodbane, D. Himbert, C. Rau, R. Raffoul, D. Messika-Zeitoun, E. Brochet, A. Vahanian, and P. Nataf Unexpected Complications of Transapical Aortic Valve Implantation Ann. Thorac. Surg., July 1, 2009; 88(1): 90 - 94. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |